Anti-VEGF therapy, therefore, not only reduces excessive angiogenesis and normalises the tumour vessel structure to improve drug perfusion and efficacy, but it also has the potential to reprogram the TME from an immune suppressive to immune permissive microenvironment. Here, VEGFA is linked to neoplasm.